Clinical trial nabs SEC attention

Share this article:

A Securities and Exchange Commission investigation has added a new angle to the clinical trial world: the potential for insider trading. The government agency announced Monday that it has accused two California doctors of illegally using non-public information to make money.

The SEC says the two doctors had agreed to provide services as part of a clinical trial for GTx, which was testing its prostate cancer drug Capesaris. The doctors were paid for their participation in the study, and the SEC notes the contracts “contained strict confidentiality provisions” that kept the physicians from “using non-public information about the trials for any purpose other than rendering services.”

The SEC alleges that the doctors sold GTx stock after the drugmaker said the FDA idled the trials over safety concerns, and before GTx made this news public. The SEC says the doctors saved close to a combined $46,000 because they were able to unload stock before the news depressed share prices.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.